Oncology Thought Leaders Assess Lead Compounds in Development for Ovarian Cancer
(PRWEB) February 11, 2010 -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat ovarian cancer.
Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15,000 women die each year in the US from ovarian cancer. While the 5-year survival for non-metastatic disease is 75%, only 20% of metastatic patients live this long. Thus there is an urgent unmet need for improved treatment strategies for ovarian cancer
This report, entitled “Thought Leader Insight & Analysis – Ovarian Cancer,” summarizes the perspectives of highly regarded U.S. based ovarian cancer specialists. In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics.
“The “next big thing” will be Avastin, so our panel evaluates inhibitors of PARP and mTOR/PI3K/AKT (& MEK) in a world where oncologists have moved from platinum doublets to a triplet containing bevacizumab, carboplatin and paclitaxel/gemcitabine/doxorubicin,” according to Jeff Berk, the report’s lead author. “The panel identifies strengths and weaknesses for lead compounds amongst the most important mechanisms in development for ovarian cancer.”
The report provides analysis of the following types of mechanisms/targets being studied:
• VEGF/PDGF/FGF/vascular disrupting agents
• DLL4/Notch
• EGFR
• alpha-folate receptor inhibitors
• Hedgehog
• IGF1R
• Immunologic approaches
• mTOR/PI3K/AKT MEK
• miRNA/siRNA
• PARP
• Platinums
• Superoxide
• Src, and
• Taxane/Epothilone.
Companies and partnerships mentioned in this report include: Abbott, Abraxis, Amgen, AstraZeneca, Bayer Healthcare/Onyx, Boehringer Ingelheim, Bristol-Myers Squibb, Cell Therapeutics, Endocyte, Genentech, GlaxoSmithKline, Infinity, Ortho Biotech (Johnson & Johnson), Keryx, Menarini, Morphotek/Eisai, OSI Pharmaceuticals/Genentech, OxiGene, Novartis, Pfizer, and Sanofi-Aventis.
This report can be purchased by contacting MedPredict at (513) 271-1924.
About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
# # #
This press release has been reprinted from PRWEB per the terms and conditions of the copyright notice.
|
|
 |
 |
|
Ovations For the Cure Elects Corporate Family Network President/CEO Linda John to Board
John brings more than 25 years of business acumen to the ovarian cancer non-profit's board.
What Does Ovarian Cancer Look Like on an Ultrasound
Ovarian cancer varies in seriousness from slow growing to aggressively invasive They may be solid, fluid-filled or a combination of both
Endometriosis Versus Ovarian Cancer
For a number of Endometriosis sufferers who also have a family history of cancer, ovarian cancer can be a concern. Having Endometriosis does not mean that you will definitely develop ovarian cancer, however a higher percentage of Endo sufferers do end up with this disease too. So, is there any link between Endometriosis versus ovarian cancer, or are these two illnesses distinct and separate?
Ovations for the Cure Founder Receives Teal Ribbon Award
Patricia Franchi Flaherty Honored During National Ovarian Cancer Awareness Month.
Emerging Signs Connected With Ovarian Cancer
If a woman is diagnosed with ovarian cancer during the early stages of the disease, her survival rates are excellent (75%) - that means it's critical to keep an eye on potential ovarian cancer warning signs
A woman's chances of survival are strong if the ovarian cancer is caught early, but approximately 75% of women are diagnosed after it has already spread beyond the ovaries, and this is when survival rates drop to only around 20 or 30 percent
Must Know Facts About Ovarian Cancer
Do you find yourself searching for facts about ovarian cancer
Well here are a couple quick facts for you
New Hope for Ovarian Cancer Patients Seeking Motherhood After Treatment: NY Methodist Experts Discuss Recent Research and Novel Techniques to Help Pre
According to Dr. Katherine Economos, Clinical Associate Professor of Obstetrics & Gynecology at Weill Medical College of Cornell University and Director of the Division of Gynecologic Oncology at New York Methodist Hospital, "With the diagnosis of ovarian cancer in a patient of childbearing age, the most important first-step is to consult with both a gynecologic oncologist and a fertility specialist. It is crucial that these two areas of practice and expertise merge to determine the best course of treatment, each step of the way, that will result in a cancer-free diagnosis and the potential for future fertility and motherhood.
National Ovarian Cancer Coalition Offers a New Charity Driven Auto-Buying and Leasing Platform Provided by DriveWise Auto
DriveWise Auto signs an agreement with the National Ovarian Cancer Coalition making its Charity Driven Auto Buying and Leasing platform available to the supporters, employees and donor base of NOCC's statewide California Chapters. Vehicles leased or purchased from DriveWise Auto by NOCC's community or those who support ovarian cancer research will yield a donation from DriveWise Auto of between $50 and $100 per vehicle.
Ovarian Cancer Symptoms
Cancer of the ovary, a disease affecting one of both of the ovaries, is one of the most serious and under-recognized ailments affecting women. In United States, it is considered as the fifth among the most fatal gynecologic cancers (affecting the female reproductive organs). It is said that in every 57 women, one may be diagnosed with ovarian cancer and almost half of those women diagnosed with the said cancer may die in a span of five years.
|
 |
|
